Phase I trial evaluating the tolerability of low-dose vs high-dose sufentanil/triazolam vs sufentanil alone in patients undergoing office-based procedures

Trial Profile

Phase I trial evaluating the tolerability of low-dose vs high-dose sufentanil/triazolam vs sufentanil alone in patients undergoing office-based procedures

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jan 2009

At a glance

  • Drugs Sufentanil/triazolam (Primary) ; Sufentanil
  • Indications Anxiety disorders; Procedural pain
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Jan 2009 New trial record.
    • 12 Jan 2009 Results reported by AcelRx in a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top